Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

By L. Tanoue. 2011

1,631 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ae3c5ba5f82db635cf20df2c004b1d8acb8a1ec5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. Gregory Riely
3. Jie Yang
4. M. Kris
5. J. Chmielecki
6. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. William Pao
2. Gregory Riely
3. J. Chmielecki
4. M. Kris
5. Marc Ladanyi
6. L. Sequist

Citations in the corpus

• Harnessing multimodal data integration to advance precision oncology (2021, background): “Active endogenous mutational processes melanoma 43 , EGFR in NSCLC 44 , ERBB2 (also known as HER2 ) in breast cancer 45 , IDH1 in acute myeloid leukaemia (AML) 46 , BRCA1 or BRCA2 in ovarian cancer 47 and prostate cancer 48 and even rare events such as neurotrophic tyrosine kinase (NTRK) fusions 49…”
• Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016, neutral): “The gene targets covered by this assay are as follows (exons): AKT1 (3), ALK (22, 23, 25), APC (16), BRAF (11, 15), CDH1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16), CDKN2A (1, 2, 3), CTNNB1 (3), DDR2 (12, 13, 14, 15, 16, 17, 18), EGFR (7, 15, 18, 19, 20, 21), ERBB2 (10, 20), ESR1 (8), FB”
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016, neutral): “Aspartate aminotransferase elevation 14 (5) 3 (1) 15 (11) 1 (1)”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “provement in progression-free survival (PFS) compared with chemotherapy.(2-6) The trials have all”
• Glucocorticoid Receptor Confers Resistance to Anti-Androgens by Bypassing Androgen Receptor Blockade (2013, neutral): “Clinical success of kinase inhibitors in other tumors such as melanoma, lung cancer, leukemia, and sarcoma is similarly transient (Sawyers et al., 2002; Chapman et al., 2011; Demetri et al., 2002; Maemondo et al., 2010), resulting in numerous efforts to define mechanisms of acquired resistance.”
• Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. (2015, background): “These latter numbers are not dissimilar from data available for other oncogene-driven NSCLCs treated with TKIs, such as epidermal growth factor receptor (EGFR) –mutated NSCLC treated with gefitinib or erlotinib.(32,33) In one report of EGFR-mutated NSCLC, the cumulative incidence of brain metastases”
• Molecular Epidemiology of EGFR and KRAS Mutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-related KRAS-mutant Cancers (2012, background): “However, the better clinical outcome of patients with EGFR exon 19 del compared with patients harboring EGFR L858Rmutations remains controversial; 2 prospective randomized phase III trial studies did not confirm these observations (35, 36).”
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015, neutral): “Any grade 5 (24) 5 (9) 9 (10) 5 (8) 1 (5) 25 (10)”
• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “Recent studies evaluating EGFR TKIs in patients with these activating EGFR gene mutations demonstrated a consistent improvement in progression-free survival, but none of these trials have demonstrated an improvement in overall survival [126-128].”